Source: Health Products Regulatory Authority (ZA) Revision Year: 2023 Publisher: Pharma Dynamics (Pty) Ltd, 1<sup>st</sup> Floor, Grapevine House, Steenberg Office Park, Silverwood Close, Westlake, Cape Town, 7945, South Africa
Pharmacotherapeutic group: antihistamine for systemic use, piperazine derivatives
ATC code: R06AE09
Pharmacological classification: A 5.7.1 Antihistaminic
Levocetirizine, the R-enantiomer of cetirizine, is a histamine H1 receptor antagonist.
Levocetirizine is absorbed after oral administration with peak blood levels reached 0,9 hours after oral administration.
Levocetirizine is 90% bound to human plasma proteins.
The extent of metabolism is less than 14% of the dose.
The plasma half-life is approximately 8 hours in adults. The half-life is shorter in small children. The main route of excretion is via urine, accounting for approximately 85% of the dose. Approximately 13% is excreted in the faeces.
Plasma levels rise in a linear manner between 2,5 mg and 20 mg.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
